Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is This Biotech an Undiscovered Gem?

By Dave Williamson - Apr 3, 2013 at 6:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Could this company be a diamond in the rough for investors?

Biotech Astex Pharmaceuticals (NASDAQ: ASTX) made a huge pop today, after RBC gave the stock an upgrade to "outperform," calling it an "undiscovered gem" and raising the price target a whopping 40%. In this video, Motley Fool health-care analyst David Williamson tells investors about some potentially very exciting phase 2 data soon to be released by the company and gives us a picture of what it could mean for Astex if its trial data is as good as RBC thinks.

Stocks Mentioned

Johnson & Johnson

JNJ

$176.98 (1.75%) $3.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Better Buy: Gingko Bioworks vs. Amyris

Have $2,000? 2 Market Crash-Ready Stocks to Buy

Stock Market Plunge: 5 Unstoppable Stocks on Sale to Buy Now and Hold Forever

2 Safe Stocks to Buy in a Bear Market

Tech Stock Sell-Off Got You Scared? Here's a Better Buy.

Motley Fool Returns

Market-beating stocks from our award-winning service.

Stock Advisor Returns

330%

S&P 500 Returns

115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.